MDxHealth (NASDAQ:MDXH) Price Target Raised to $7.00 at TD Cowen

MDxHealth (NASDAQ:MDXH) had its price target boosted by investment analysts at TD Cowen from $5.00 to $7.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s target price suggests a potential upside of 72.41% from the stock’s previous close.

Several other research analysts have also weighed in on MDXH. Weiss Ratings restated a “sell (e+)” rating on shares of MDxHealth in a research report on Wednesday, October 8th. BTIG Research upped their price target on MDxHealth from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Thursday. Lake Street Capital raised their price objective on MDxHealth from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday. Wall Street Zen upgraded MDxHealth to a “hold” rating in a research report on Saturday, August 30th. Finally, Craig Hallum began coverage on MDxHealth in a report on Thursday, July 17th. They issued a “buy” rating and a $8.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.75.

MDxHealth Price Performance

Shares of MDxHealth stock traded down $0.06 during trading on Thursday, reaching $4.06. The company’s stock had a trading volume of 195,657 shares, compared to its average volume of 120,087. MDxHealth has a 12-month low of $1.35 and a 12-month high of $5.33. The company has a quick ratio of 1.22, a current ratio of 1.31 and a debt-to-equity ratio of 13.81. The business has a 50 day moving average price of $4.31 and a 200-day moving average price of $3.04. The company has a market capitalization of $191.99 million, a P/E ratio of -4.61 and a beta of 1.68.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The company had revenue of $27.43 million for the quarter, compared to analyst estimates of $24.11 million. MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%. MDxHealth has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that MDxHealth will post -1.15 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in MDXH. AWM Investment Company Inc. boosted its holdings in shares of MDxHealth by 10.6% during the first quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company’s stock worth $7,414,000 after purchasing an additional 499,992 shares during the last quarter. Perkins Capital Management Inc. lifted its position in MDxHealth by 20.1% during the first quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company’s stock worth $1,678,000 after buying an additional 198,000 shares during the period. Delta Investment Management LLC lifted its position in MDxHealth by 459.1% during the first quarter. Delta Investment Management LLC now owns 190,100 shares of the company’s stock worth $270,000 after buying an additional 156,100 shares during the period. FreeGulliver LLC acquired a new stake in MDxHealth in the 2nd quarter worth about $273,000. Finally, Russell Investments Group Ltd. purchased a new stake in MDxHealth in the 3rd quarter valued at about $461,000.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.